{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T08:42:20Z","timestamp":1761986540623,"version":"build-2065373602"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002894","name":"Foundation of the American College of Allergy, Asthma & Immunology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002894","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.anai.2020.06.041","type":"journal-article","created":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T12:46:56Z","timestamp":1593780416000},"page":"433-439","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical use of biologics for asthma treatment by allergy specialists"],"prefix":"10.1016","volume":"125","author":[{"given":"Merin","family":"Kuruvilla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Ariue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J.","family":"Oppenheimer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1830-6262","authenticated-orcid":false,"given":"Umesh","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan A.","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.anai.2020.06.041_bib1","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jaip.2014.09.007","article-title":"Developing and emerging clinical asthma phenotypes","volume":"2","author":"Hekking","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.anai.2020.06.041_bib2","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.pcl.2019.06.001","article-title":"New treatments for asthma","volume":"66","author":"Huang","year":"2019","journal-title":"Pediatr Clin North Am"},{"issue":"1","key":"10.1016\/j.anai.2020.06.041_bib3","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.anai.2019.10.016","article-title":"Asthma biologics: comparing trial designs, patient cohorts and study results","volume":"124","author":"Doroudchi","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"10.1016\/j.anai.2020.06.041_bib4","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.anai.2019.07.012","article-title":"Choosing the right biologic for severe asthma: precision medicine through the lens of patient-centered decision making","volume":"123","author":"Desai","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"152","key":"10.1016\/j.anai.2020.06.041_bib5","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0054-2019","article-title":"Severe T2-high asthma in the biologics era: European experts\u2019 opinion","volume":"28","author":"Pavord","year":"2019","journal-title":"Eur Respir Rev"},{"issue":"6","key":"10.1016\/j.anai.2020.06.041_bib6","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1057\/palgrave.jibs.8400396","article-title":"Data equivalence in cross-cultural international business research: assessment and guidelines","volume":"39","author":"Hult","year":"2008","journal-title":"J\u00a0Int Bus Stud"},{"issue":"1","key":"10.1016\/j.anai.2020.06.041_bib8","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jaci.2018.08.031","article-title":"Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: indirect treatment comparison","volume":"143","author":"Busse","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2020.06.041_bib9","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1080\/02770903.2018.1471708","article-title":"Treatment of severe, uncontrolled eosinophilic asthma: where we are heading","volume":"56","author":"Bernstein","year":"2019","journal-title":"J\u00a0Asthma"},{"key":"10.1016\/j.anai.2020.06.041_bib10","first-page":"CD010834","article-title":"Anti-IL5 therapies for asthma","volume":"9","author":"Farne","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.anai.2020.06.041_bib11","first-page":"55","article-title":"Omalizumab: the evidence for its place in the treatment of allergic asthma","volume":"3","author":"McNicholl","year":"2008","journal-title":"Core Evid"},{"issue":"26","key":"10.1016\/j.anai.2020.06.041_bib12","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.anai.2020.06.041_bib13","doi-asserted-by":"crossref","first-page":"1900588","DOI":"10.1183\/13993003.00588-2019","article-title":"Management of severe asthma: a European Respiratory Society\/American Thoracic Society guideline","volume":"55","author":"Holguin","year":"2020","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.anai.2020.06.041_bib14","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.jaip.2019.03.008","article-title":"Biologics for severe asthma: treatment-specific effects are important in choosing a specific agent","volume":"7","author":"Krings","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.anai.2020.06.041_bib15","doi-asserted-by":"crossref","first-page":"1701782","DOI":"10.1183\/13993003.01782-2017","article-title":"Care pathways for the selection of a biologic in severe asthma","volume":"50","author":"Bousquet","year":"2017","journal-title":"Eur Respir J"},{"issue":"26","key":"10.1016\/j.anai.2020.06.041_bib16","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1056\/NEJMe1806037","article-title":"New biologics for asthma","volume":"378","author":"Drazen","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.anai.2020.06.041_bib17","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.jaci.2015.09.034","article-title":"Omalizumab reduces cysteinyl leukotriene and 9alpha,11beta-prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease","volume":"137","author":"Hayashi","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.anai.2020.06.041_bib18","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1016\/j.jaip.2019.03.044","article-title":"Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD","volume":"7","author":"Laidlaw","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2020.06.041_bib19","article-title":"Effects of the first three doses of Benralizumab on symptom control, lung function, blood eosinophils, oral corticosteroid intake, and nasal polyps in a patient with severe allergic asthma","volume":"8","author":"Pelaia","year":"2020","journal-title":"SAGE Open Med Case Rep"},{"issue":"3","key":"10.1016\/j.anai.2020.06.041_bib20","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jaip.2018.01.038","article-title":"A\u00a0retrospective analysis of mepolizumab in subjects with aspirin-exacerbated respiratory disease","volume":"6","author":"Tuttle","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.anai.2020.06.041_bib21","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jaip.2018.08.021","article-title":"Effects of reslizumab on asthma outcomes in a subgroup of eosinophilic asthma patients with self-reported chronic rhinosinusitis with nasal polyps","volume":"7","author":"Weinstein","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.anai.2020.06.041_bib22","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1183\/09031936.00012415","article-title":"Biomarkers to identify sputum eosinophilia in different adult asthma phenotypes","volume":"46","author":"Westerhof","year":"2015","journal-title":"Eur Respir J"},{"issue":"8","key":"10.1016\/j.anai.2020.06.041_bib23","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1164\/rccm.201208-1414OC","article-title":"Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study","volume":"187","author":"Hanania","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.anai.2020.06.041_bib24","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jaip.2015.08.003","article-title":"Utilization and costs of severe uncontrolled asthma in a managed-care setting","volume":"4","author":"Zeiger","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.anai.2020.06.041_bib25","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.anai.2019.01.018","article-title":"Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: to biologic or not to biologic?","volume":"122","author":"Anderson","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"10.1016\/j.anai.2020.06.041_bib26","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.anai.2018.12.016","article-title":"Asthma biologics: underuse, overuse, and best use?","volume":"122","author":"Rank","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"10.1016\/j.anai.2020.06.041_bib27","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jaci.2015.09.008","article-title":"Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations","volume":"136","author":"Teach","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"year":"2020","series-title":"GINA Report, Global Strategy for Asthma Management and Prevention","key":"10.1016\/j.anai.2020.06.041_bib28"},{"issue":"5","key":"10.1016\/j.anai.2020.06.041_bib29","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.jaip.2018.07.007","article-title":"How important is adherence to inhaled medications before starting a biologic therapy for asthma?","volume":"6","author":"Corren","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.anai.2020.06.041_bib30","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/MCP.0000000000000334","article-title":"Improving adherence to asthma medications: current knowledge and future perspectives","volume":"23","author":"Blake","year":"2017","journal-title":"Curr Opin Pulm Med"},{"issue":"5","key":"10.1016\/j.anai.2020.06.041_bib31","article-title":"Adherence to corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma","volume":"55","author":"d\u2019Ancona","year":"2020","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.anai.2020.06.041_bib32","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.jaip.2017.07.034","article-title":"Trends in omalizumab utilization for asthma: evidence of suboptimal patient selection","volume":"6","author":"Jeffery","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.anai.2020.06.041_bib33","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.anai.2017.09.056","article-title":"Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO","volume":"119","author":"Chipps","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"10","key":"10.1016\/j.anai.2020.06.041_bib34","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1164\/rccm.201903-0599LE","article-title":"Prognostic and predictive value of blood eosinophil count, fractional exhaled nitric oxide, and their combination in severe asthma: A post hoc analysis","volume":"200","author":"Shrimanker","year":"2019","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120620304452?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120620304452?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:24:35Z","timestamp":1761053075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120620304452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S1081120620304452"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2020.06.041","relation":{},"ISSN":["1081-1206"],"issn-type":[{"type":"print","value":"1081-1206"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical use of biologics for asthma treatment by allergy specialists","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2020.06.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}